IPO Timeline
Broker Results (T-2)
2022-11-02
Some brokers release in afternoon
Grey Market (T-1)
2022-11-03
Afternoon
HKEX Allotment (T-1)
2022-11-03
Evening
Registrar Allotment (T-1)
2022-11-03
Evening
Listing Day (T)
2022-11-04
First day of trading
Company Overview
| Stock Name | 巨子生物 |
|---|---|
| Stock Code | 02367 |
| Company Full Name | 巨子生物 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事研究、開發、制造和銷售基於生物活性成分的皮膚護理產品及健康食品。 |
| Listing Date | 2022-11-04 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國陜西省西安市長安區上林苑七路1855號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.xajuzi.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 24.30 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 54,947,160 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 4,860 |
| 2 lots | 400 | HK$ 9,720 |
| 3 lots | 600 | HK$ 14,580 |
| 4 lots | 800 | HK$ 19,440 |
| 5 lots | 1,000 | HK$ 24,300 |
| 6 lots | 1,200 | HK$ 29,160 |
| 7 lots | 1,400 | HK$ 34,020 |
| 8 lots | 1,600 | HK$ 38,880 |
| 9 lots | 1,800 | HK$ 43,740 |
| 10 lots | 2,000 | HK$ 48,600 |
| 15 lots | 3,000 | HK$ 72,900 |
| 20 lots | 4,000 | HK$ 97,200 |
| 25 lots | 5,000 | HK$ 121,500 |
| 30 lots | 6,000 | HK$ 145,800 |
| 35 lots | 7,000 | HK$ 170,100 |
| 40 lots | 8,000 | HK$ 194,400 |
| 45 lots | 9,000 | HK$ 218,700 |
| 50 lots | 10,000 | HK$ 243,000 |
| 75 lots | 15,000 | HK$ 364,500 |
| 100 lots | 20,000 | HK$ 486,000 |
| 125 lots | 25,000 | HK$ 607,500 |
| 150 lots | 30,000 | HK$ 729,000 |
| 175 lots | 35,000 | HK$ 850,500 |
| 200 lots | 40,000 | HK$ 972,000 |
| 225 lots | 45,000 | HK$ 1,093,500 |
| 250 lots | 50,000 | HK$ 1,215,000 |
| 300 lots | 60,000 | HK$ 1,458,000 |
| 350 lots | 70,000 | HK$ 1,701,000 |
| 450 lots | 90,000 | HK$ 2,187,000 |
| 500 lots | 100,000 | HK$ 2,430,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 26.7 |
|---|---|
| First Day Open | HK$ 26.0 |
| First Day Change | 9.88% |
| First Day Volume | 7243000.0 |
| First Day Turnover | 202303000.0 |
Use of Proceeds
| Use of Proceeds | 1、約11%的所得款項凈額（即54.5百萬港元）用于研發投資以通過招聘擴大我們的研發團隊、擴展我們的研發設施及進行測試和驗證研究； 2、約28%的所得款項凈額（即138.8百萬港元）用于擴展與我們的產品組合及生物活性成分有關的生產能力； 3、約46%的所得款項凈額（即228.1百萬港元），用于增強我們的全渠道銷售及經銷網絡，并開展以科學和知識為導向的營銷活動以提高我們的品牌知名度； 4、約5%的所得款項凈額（即24.8百萬港元）用于提升我們運營及信息系統； 5、約10%的所得款項凈額（即49.6百萬港元）用作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
华泰金融控股（香港）有限公司 CE AOK809
Joint Lead Managers (6)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
华泰金融控股（香港）有限公司 CE AOK809
GF Securities (Hong Kong) Brokerage Limited CE AOB364
富途证券国际（香港）有限公司 CE AZT137
元库证券有限公司 CE BLN458
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 嚴建亞 |
|---|---|
| Company Secretary | 嚴鈺博;歐陽麗妮 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 范代娣及關連人士(60.4%) |
|---|
Subscription Tiers
IPO Timeline
